Novel drug treatments for schizophrenia.
(2026) Prime editing to suppress nonsense mutations.
(2026) Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications.
(2026) Promoting prostaglandin signalling for joint repair in osteoarthritis.
(2026) 2025 FDA approvals.
(2026) First antibody-mimetic adnectin nabs an FDA approval.
(2026) Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories.
(2026) Redirecting mast cells for antigen-specific cancer immunotherapy.
(2026) Nonopioid analgesic alleviates neuropathic pain.
(2026) Histone methyltransferase inhibition hampers prostate cancer.
(2026) Kinase inhibitors trigger target degradation.
(2026) Boosting CAR T cell efficacy.
(2026) Innate immune receptor agonist for cancer immunotherapy.
(2026) Biopharma dealmaking in 2025.
(2026) 2025 FDA approvals: volume maintained, but value remains below average.
(2026) Hunting for biopharma's innovation sweet spot.
(2026) Strategies for blood-brain barrier rejuvenation and repair.
(2026) Roads and detours for CAR T cell therapy in autoimmune diseases.
(2026) Epigenetic inhibitor silences KRAS-driven oncogenes
vol.24 iss.10 (2025) pp.1 Gut microbiota–derived metabolite drives atherosclerosis
vol.24 iss.10 (2025) pp.1 FDA new drug approvals in Q2 2025
vol.24 iss.8 (2025) pp.1 A neonatal window for in vivo gene therapy in haematopoietic stem cells.
vol.24 iss.8 (2025) In utero ASO therapy for spinal muscular atrophy
vol.24 iss.7 (2025) pp.1 Top companies and drugs by sales in 2024
vol.24 iss.4 (2025) pp.1 Outlook for medicines development and use in 2025.
vol.24 iss.2 (2025) 2024 FDA approvals.
vol.24 iss.2 (2025) FDA approves next-generation triple therapy for cystic fibrosis.
vol.24 iss.2 (2025) DLL3 draws two antibody-drug conjugate deals.
vol.24 iss.2 (2025) 2024 FDA approvals exceed average number but have lower sales projections.
vol.24 iss.2 (2025) Biopharma dealmaking in 2024.
vol.24 iss.2 (2025) Engineered T cells traverse new terrain.
vol.24 iss.2 (2025) Pairing up with GLP-1 to combat obesity.
vol.24 iss.2 (2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
vol.24 iss.2 (2025) Cough suppressant reverses lung scarring.
vol.24 iss.2 (2025) Harnessing the biology of regulatory T cells to treat disease.
vol.24 iss.2 (2025) Targeting lysine acetylation readers and writers.
vol.24 iss.2 (2025) Vaccines for cancer prevention: exploring opportunities and navigating challenges.
vol.24 iss.2 (2025) Antiviral target compound profile for pandemic preparedness.
vol.24 iss.2 (2025) The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships.
vol.24 iss.1 (2025) Na V 1.8 inhibitor poised to provide opioid-free pain relief.
vol.24 iss.1 (2025) FDA approves L-amino acid decarboxylase deficiency gene therapy.
vol.24 iss.1 (2025) FDA approves first menin inhibitor, for acute leukaemia.
vol.24 iss.1 (2025) Top product forecasts for 2025.
vol.24 iss.1 (2025) Upcoming FDA approval decisions in Q1 2025.
vol.24 iss.1 (2025) Can non-canonical amino acids open up non-canonical drug discovery opportunities?
vol.24 iss.1 (2025) Two decades of new drug approvals in Japan.
vol.24 iss.1 (2025) StitchR platform joins up gene therapy payloads.
vol.24 iss.1 (2025) NK2R agonist delivers one-two punch to obesity.
vol.24 iss.1 (2025) Covalent inhibitor engages oncogenic AKT kinase.
vol.24 iss.1 (2025) ENGases to treat IgG-mediated diseases.
vol.24 iss.1 (2025)
(2026) Prime editing to suppress nonsense mutations.
(2026) Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications.
(2026) Promoting prostaglandin signalling for joint repair in osteoarthritis.
(2026) 2025 FDA approvals.
(2026) First antibody-mimetic adnectin nabs an FDA approval.
(2026) Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories.
(2026) Redirecting mast cells for antigen-specific cancer immunotherapy.
(2026) Nonopioid analgesic alleviates neuropathic pain.
(2026) Histone methyltransferase inhibition hampers prostate cancer.
(2026) Kinase inhibitors trigger target degradation.
(2026) Boosting CAR T cell efficacy.
(2026) Innate immune receptor agonist for cancer immunotherapy.
(2026) Biopharma dealmaking in 2025.
(2026) 2025 FDA approvals: volume maintained, but value remains below average.
(2026) Hunting for biopharma's innovation sweet spot.
(2026) Strategies for blood-brain barrier rejuvenation and repair.
(2026) Roads and detours for CAR T cell therapy in autoimmune diseases.
(2026) Epigenetic inhibitor silences KRAS-driven oncogenes
vol.24 iss.10 (2025) pp.1 Gut microbiota–derived metabolite drives atherosclerosis
vol.24 iss.10 (2025) pp.1 FDA new drug approvals in Q2 2025
vol.24 iss.8 (2025) pp.1 A neonatal window for in vivo gene therapy in haematopoietic stem cells.
vol.24 iss.8 (2025) In utero ASO therapy for spinal muscular atrophy
vol.24 iss.7 (2025) pp.1 Top companies and drugs by sales in 2024
vol.24 iss.4 (2025) pp.1 Outlook for medicines development and use in 2025.
vol.24 iss.2 (2025) 2024 FDA approvals.
vol.24 iss.2 (2025) FDA approves next-generation triple therapy for cystic fibrosis.
vol.24 iss.2 (2025) DLL3 draws two antibody-drug conjugate deals.
vol.24 iss.2 (2025) 2024 FDA approvals exceed average number but have lower sales projections.
vol.24 iss.2 (2025) Biopharma dealmaking in 2024.
vol.24 iss.2 (2025) Engineered T cells traverse new terrain.
vol.24 iss.2 (2025) Pairing up with GLP-1 to combat obesity.
vol.24 iss.2 (2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
vol.24 iss.2 (2025) Cough suppressant reverses lung scarring.
vol.24 iss.2 (2025) Harnessing the biology of regulatory T cells to treat disease.
vol.24 iss.2 (2025) Targeting lysine acetylation readers and writers.
vol.24 iss.2 (2025) Vaccines for cancer prevention: exploring opportunities and navigating challenges.
vol.24 iss.2 (2025) Antiviral target compound profile for pandemic preparedness.
vol.24 iss.2 (2025) The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships.
vol.24 iss.1 (2025) Na V 1.8 inhibitor poised to provide opioid-free pain relief.
vol.24 iss.1 (2025) FDA approves L-amino acid decarboxylase deficiency gene therapy.
vol.24 iss.1 (2025) FDA approves first menin inhibitor, for acute leukaemia.
vol.24 iss.1 (2025) Top product forecasts for 2025.
vol.24 iss.1 (2025) Upcoming FDA approval decisions in Q1 2025.
vol.24 iss.1 (2025) Can non-canonical amino acids open up non-canonical drug discovery opportunities?
vol.24 iss.1 (2025) Two decades of new drug approvals in Japan.
vol.24 iss.1 (2025) StitchR platform joins up gene therapy payloads.
vol.24 iss.1 (2025) NK2R agonist delivers one-two punch to obesity.
vol.24 iss.1 (2025) Covalent inhibitor engages oncogenic AKT kinase.
vol.24 iss.1 (2025) ENGases to treat IgG-mediated diseases.
vol.24 iss.1 (2025)
